CAR T-cell therapy is a one-time intensive treatment that could potentially lead to a long remission, where Tec-Dara is an ...

InoPd with inobrodib 20 mg previously demonstrated response rates at least 2x greater than alternatives for heavily pretreated pomalidomide-refractory patients following bispecific T cell engager or ...

Joseph Mikhael, MD, has spent decades advancing the treatment of multiple myeloma, and he’s been witness to a remarkable ...

Genetic testing should be offered to myeloma patients to identify high-risk cases earlier and enable more targeted and effective treatment, according to experts. A study by The Institute of Cancer ...

Relapsed and refractory multiple myeloma can be difficult to manage, especially as patients progress through multiple lines of therapy and treatment options may become more limited. 1 Since the ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Multiple myeloma is a common blood cancer affecting plasma ...

Rahul Banerjee, MD, FACP, assistant professor in the Division of Hematology and Oncology, at the University of Washington, determines the optimal use of minimal residual disease (MRD) in individual ...

Panelists discuss how patients newly diagnosed with multiple myeloma often face emotional and informational overload, but collaborative, personalized care—including early access to cutting-edge ...

The second most common cancer in the hematologic (blood) cancer category is multiple myeloma. It accounts for about 13% of all cases of blood cancer. 63% of ...

There are now two very powerful but very different approaches that can be considered as early as first relapse for patients ...

Radiation therapy is a treatment that uses high doses of radiation to damage cancer cells, either killing them or slowing their growth. Unlike the low-dose radiation used in X-rays to see inside the ...

However, since CD38 antibody exposure is now standard of care for both transplant-eligible and ineligible populations in 2026 ...